Association Between Systemic Neuroinflammation, Pain Perception and Clinical Status in Fibromyalgia Patients: Cross-Sectional Study

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 20; p. 1719
• Main Authors: González-Álvarez, María Elena, Riquelme-Aguado, Víctor, González-Pérez, Ángela, Murillo-Llergo, Rosa, Manjón-Olmedillas, María, Turroni, Silvia, Rossettini, Giacomo, Villafañe, Jorge Hugo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.10.2024; MDPI
• Subjects: Adult; Biomarkers - blood; Blood levels; Body mass index; Chronic pain; Cross-Sectional Studies; Disability; Female; Fibromyalgia; Fibromyalgia - blood; Glucose; Humans; Immunoassay; Inflammation; Inflammation - blood; Insulin resistance; Interleukin 6; Interleukin 8; Interleukin-6 - blood; Interleukin-8 - blood; Interleukins; Male; Medical research; Medicine, Experimental; Metabolism; Middle Aged; Nervous system; neuroinflammation; Neuroinflammatory Diseases - blood; Neuroinflammatory Diseases - immunology; Neuromodulation; Pain Measurement; Pain Perception; Patients; Questionnaires; Social networks; Surveys and Questionnaires; Spain; Madrid Spain; fibromyalgia; neuroinflammation; interleukins
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells13201719

Fibromyalgia (FM) is characterized by chronic pain and a complex array of symptoms, with neuroinflammation implicated in its pathophysiology. This study aimed to explore the association between neuroinflammation, measured through interleukin levels (IL-1, IL-6, IL-8), and clinical outcomes in FM patients. Using a cross-sectional study design, blood levels of these interleukins were correlated with pain severity and disability, assessed via the Fibromyalgia Impact Questionnaire (FIQ) and pain measures. Results indicated that IL-6 and IL-8 may particularly serve as biomarkers for pain severity and disability in FM patients, showing significant associations with worse clinical outcomes. Elevated IL-8 levels, for instance, correlated strongly with increased pain perception and higher disability scores. These findings suggest that specific interleukins are not only elevated in FM but are actively involved in the modulation of pain and disability, underscoring the role of systemic neuroinflammation in the clinical severity of FM. This study contributes to a deeper understanding of the inflammatory mechanisms in FM and underscores the potential of targeting interleukins in therapeutic strategies.